The SOX17 phenotype in pulmonary arterial hypertension: lessons for pathobiology and clinical management

Jurjan Aman; Nicholas W. Morrell; Christopher J. Rhodes; Martin R. Wilkins; Harm Jan Bogaard

doi:10.1183/13993003.01438-2022

The SOX17 phenotype in pulmonary arterial hypertension: lessons for pathobiology and clinical management

Jurjan Aman^*
, Nicholas W. Morrell
, Christopher J. Rhodes
, Martin R. Wilkins
, Harm Jan Bogaard

^*Corresponding author for this work

University of Cambridge
Imperial College London
Amsterdam UMC - University of Amsterdam
Amsterdam University Medical Centers

Research output: Contribution to journal › Editorial › Academic › peer-review

20 Downloads (Pure)

Original language	English
Article number	2201438
Journal	European respiratory journal
Volume	60
Issue number	6
DOIs	https://doi.org/10.1183/13993003.01438-2022
Publication status	Published - 1 Dec 2022

Access to Document

10.1183/13993003.01438-2022

The-sox17-phenotype-in-pulmonary-arterial-hypertension.pdfFinal published version, 214 KBLicence: CC BY

Cite this

@article{15309f41d0784d0fabf64b54606c9cbc,

title = "The SOX17 phenotype in pulmonary arterial hypertension: lessons for pathobiology and clinical management",

author = "Jurjan Aman and Morrell, \{Nicholas W.\} and Rhodes, \{Christopher J.\} and Wilkins, \{Martin R.\} and Bogaard, \{Harm Jan\}",

note = "Funding Information: Support statement: J. Aman received a fellowship from the Dutch Research Council (NWO VENI: \#09150161910155). N.W. Morrell received support from the British Heart Foundation. C.J Rhodes received fellowships from the British Heart Foundation (FS/15/59/31839) and from the Academy of Medical Sciences (SBF004\textbackslash{}1095). M.R. Wilkins received support from the British Heart Foundation, the National Institute for Health and Care Research, Morphogenix, Janssen, Novartis and Acceleron. H.J. Bogaard received grant support from the Dutch Cardiovascular Alliance (DOLPHIN-GENESIS (CVON2017-10). Funding Information: Conflict of interest: J. Aman reports grants from NWO VENI (\#09150161910155). N.W. Morrell reports grants from British Heart Foundation to support the present manuscript. C.J Rhodes reports the following support for the present manuscript: BHF fellowship (FS/15/59/31839) and Academy of Medical Sciences Springboard fellowship (SBF004\textbackslash{}1095); C.J. Rhodes also reports advisory board participation (including consulting fees and travel support) with United Therapeutics and Janssen ( J\&J); and a patent submitted for prognostic protein model with Imperial Innovations; outside the submitted work. M.R. Wilkins reports the following support for the present manuscript: British Heart Foundation (SP/12/12/29836) and BHF Imperial Research Centre of Excellence award (RE/18/4/34215); M.R. Wilkins also reports grants from British Heart Foundation, NIHR and NIH, consulting fees from MorphogenIX and Janssen, and participation on advisory boards for Acceleron and Novartis; and patents for ZIP12 as a target and miRNAs as biomarkers; outside the submitted work. H.J. Bogaard has nothing to disclose. Funding Information: J. Aman reports grants from NWO VENI (\#09150161910155). N.W. Morrell reports grants from British Heart Foundation to support the present manuscript. C.J Rhodes reports the following support for the present manuscript: BHF fellowship (FS/15/59/31839) and Academy of Medical Sciences Springboard fellowship (SBF004\textbackslash{}1095); C.J. Rhodes also reports advisory board participation (including consulting fees and travel support) with United Therapeutics and Janssen (J\&J); and a patent submitted for prognostic protein model with Imperial Innovations; outside the submitted work. M.R. Wilkins reports the following support for the present manuscript: British Heart Foundation (SP/12/12/29836) and BHF Imperial Research Centre of Excellence award (RE/18/4/34215); M.R. Wilkins also reports grants from British Heart Foundation, NIHR and NIH, consulting fees from MorphogenIX and Janssen, and participation on advisory boards for Acceleron and Novartis; and patents for ZIP12 as a target and miRNAs as biomarkers; outside the submitted work. H.J. Bogaard has nothing to disclose.J. Aman received a fellowship from the Dutch Research Council (NWO VENI: \#09150161910155). N.W. Morrell received support from the British Heart Foundation. C.J Rhodes received fellowships from the British Heart Foundation (FS/15/59/31839) and from the Academy of Medical Sciences (SBF004\textbackslash{}1095). M.R. Wilkins received support from the British Heart Foundation, the National Institute for Health and Care Research, Morphogenix, Janssen, Novartis and Acceleron. H.J. Bogaard received grant support from the Dutch Cardiovascular Alliance (DOLPHIN-GENESIS (CVON2017-10).",

year = "2022",

month = dec,

day = "1",

doi = "10.1183/13993003.01438-2022",

language = "English",

volume = "60",

journal = "European respiratory journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "6",

}

TY - JOUR

T1 - The SOX17 phenotype in pulmonary arterial hypertension

T2 - lessons for pathobiology and clinical management

AU - Aman, Jurjan

AU - Morrell, Nicholas W.

AU - Rhodes, Christopher J.

AU - Wilkins, Martin R.

AU - Bogaard, Harm Jan

N1 - Funding Information: Support statement: J. Aman received a fellowship from the Dutch Research Council (NWO VENI: #09150161910155). N.W. Morrell received support from the British Heart Foundation. C.J Rhodes received fellowships from the British Heart Foundation (FS/15/59/31839) and from the Academy of Medical Sciences (SBF004\1095). M.R. Wilkins received support from the British Heart Foundation, the National Institute for Health and Care Research, Morphogenix, Janssen, Novartis and Acceleron. H.J. Bogaard received grant support from the Dutch Cardiovascular Alliance (DOLPHIN-GENESIS (CVON2017-10). Funding Information: Conflict of interest: J. Aman reports grants from NWO VENI (#09150161910155). N.W. Morrell reports grants from British Heart Foundation to support the present manuscript. C.J Rhodes reports the following support for the present manuscript: BHF fellowship (FS/15/59/31839) and Academy of Medical Sciences Springboard fellowship (SBF004\1095); C.J. Rhodes also reports advisory board participation (including consulting fees and travel support) with United Therapeutics and Janssen ( J&J); and a patent submitted for prognostic protein model with Imperial Innovations; outside the submitted work. M.R. Wilkins reports the following support for the present manuscript: British Heart Foundation (SP/12/12/29836) and BHF Imperial Research Centre of Excellence award (RE/18/4/34215); M.R. Wilkins also reports grants from British Heart Foundation, NIHR and NIH, consulting fees from MorphogenIX and Janssen, and participation on advisory boards for Acceleron and Novartis; and patents for ZIP12 as a target and miRNAs as biomarkers; outside the submitted work. H.J. Bogaard has nothing to disclose. Funding Information: J. Aman reports grants from NWO VENI (#09150161910155). N.W. Morrell reports grants from British Heart Foundation to support the present manuscript. C.J Rhodes reports the following support for the present manuscript: BHF fellowship (FS/15/59/31839) and Academy of Medical Sciences Springboard fellowship (SBF004\1095); C.J. Rhodes also reports advisory board participation (including consulting fees and travel support) with United Therapeutics and Janssen (J&J); and a patent submitted for prognostic protein model with Imperial Innovations; outside the submitted work. M.R. Wilkins reports the following support for the present manuscript: British Heart Foundation (SP/12/12/29836) and BHF Imperial Research Centre of Excellence award (RE/18/4/34215); M.R. Wilkins also reports grants from British Heart Foundation, NIHR and NIH, consulting fees from MorphogenIX and Janssen, and participation on advisory boards for Acceleron and Novartis; and patents for ZIP12 as a target and miRNAs as biomarkers; outside the submitted work. H.J. Bogaard has nothing to disclose.J. Aman received a fellowship from the Dutch Research Council (NWO VENI: #09150161910155). N.W. Morrell received support from the British Heart Foundation. C.J Rhodes received fellowships from the British Heart Foundation (FS/15/59/31839) and from the Academy of Medical Sciences (SBF004\1095). M.R. Wilkins received support from the British Heart Foundation, the National Institute for Health and Care Research, Morphogenix, Janssen, Novartis and Acceleron. H.J. Bogaard received grant support from the Dutch Cardiovascular Alliance (DOLPHIN-GENESIS (CVON2017-10).

PY - 2022/12/1

Y1 - 2022/12/1

UR - https://www.scopus.com/pages/publications/85144464003

UR - https://www.ncbi.nlm.nih.gov/pubmed/37651375

UR - https://www.scopus.com/pages/publications/85144464003

U2 - 10.1183/13993003.01438-2022

DO - 10.1183/13993003.01438-2022

M3 - Editorial

C2 - 37651375

SN - 0903-1936

VL - 60

JO - European respiratory journal

JF - European respiratory journal

IS - 6

M1 - 2201438

ER -

The SOX17 phenotype in pulmonary arterial hypertension: lessons for pathobiology and clinical management

Access to Document

Other files and links

Cite this